
Daniel P Hart

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1957159/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19. New England Journal of Medicine, 2020, 383, 288-290.	27.0	418
2	Diagnosis and treatment of factor <scp>VIII</scp> and <scp>IX</scp> inhibitors in congenital haemophilia: (4th edition). British Journal of Haematology, 2013, 160, 153-170.	2.5	192
3	Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood, 2013, 122, 1954-1962.	1.4	188
4	Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011. Blood, 2014, 124, 3389-3397.	1.4	110
5	Haemophilia. Nature Reviews Disease Primers, 2021, 7, 45.	30.5	103
6	Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: The THUNDER study. Haemophilia, 2019, 25, 205-212.	2.1	51
7	Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 535-548.	2.3	50
8	Adherence to Prophylaxis in Adolescents and Young Adults with Severe Haemophilia: A Quantitative Study with Patients. PLoS ONE, 2017, 12, e0169880.	2.5	39
9	Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome. Blood, 2020, 136, 1956-1967.	1.4	34
10	Inhibitors in nonsevere haemophilia A: outcome and eradication strategies. Thrombosis and Haemostasis, 2015, 114, 46-55.	3.4	33
11	Delivery of AAVâ€based gene therapy through haemophilia centres—A need for reâ€evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC. Haemophilia, 2021, 27, 967-973.	2.1	29
12	Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies. Haemophilia, 2019, 25, 398-407.	2.1	27
13	Preâ€analytical heat treatment and a <scp>FVIII ELISA</scp> improve Factor <scp>VIII</scp> antibody detection in acquired haemophilia A. British Journal of Haematology, 2014, 166, 953-956.	2.5	24
14	Treatment burden, haemostatic strategies and real world inhibitor screening practice in nonâ€severe haemophilia A. British Journal of Haematology, 2017, 176, 796-804.	2.5	21
15	Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A. Thrombosis and Haemostasis, 2015, 114, 804-811.	3.4	19
16	A largeâ€scale computational study of inhibitor risk in nonâ€severe haemophilia A. British Journal of Haematology, 2015, 168, 413-420.	2.5	19
17	Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update. Haemophilia, 2021, 27, 932-937.	2.1	16
18	Optimizing language for effective communication of gene therapy concepts with hemophilia patients: a qualitative study. Orphanet Journal of Rare Diseases, 2021, 16, 189.	2.7	15

DANIEL P HART

#	Article	IF	CITATIONS
19	International consensus recommendations on the management of people with haemophilia B. Therapeutic Advances in Hematology, 2022, 13, 204062072210852.	2.5	13
20	Gene therapy of hemophilia: Hub centres should be haemophilia centres: A joint publication of EAHAD and EHC. Haemophilia, 2022, 28, .	2.1	10
21	Re-personalization and stratification of hemophilia care in an evolving treatment landscape. Hematology, 2019, 24, 737-741.	1.5	6
22	Factor VIII cross-matches to the human proteome reduce the predicted inhibitor risk in missense mutation hemophilia A. Haematologica, 2019, 104, 599-608.	3.5	6
23	PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant) Tj ETQq1 1 2021, 27, 911-920.	0.784314 2.1	rgBT /Over 5
24	Letter in response to: Coagulation markers are independent predictors of increased oxygen requirements and thrombosis in COVIDâ€19. Journal of Thrombosis and Haemostasis, 2020, 18, 3382-3384.	3.8	4
25	Factor VIII/IX inhibitor testing practices in the United Kingdom: Results of a UKHCDO and UKNEQAS national survey. Haemophilia, 2021, 27, 490-499.	2.1	2
26	Von Willebrand factor. Clinical Medicine, 2020, 20, e279-e279.	1.9	2
27	Perioperative laboratory monitoring in congenital haemophilia patients with inhibitors. Blood Coagulation and Fibrinolysis, 2019, 30, 309-323.	1.0	1
28	The factor VIII treatment history of nonâ€severe hemophilia A—Response from original authors Abdi et al. Journal of Thrombosis and Haemostasis, 2021, 19, 2642-2644.	3.8	1
29	A Two Centre Experience Of Use Of a Dual Virally Inactivated FVIII/VWF Product (Wilate®) In Patients With Von Willebrand Disease. Blood, 2013, 122, 1112-1112.	1.4	1
30	FVIII Immunogenicity—Bioinformatic Approaches to Evaluate Inhibitor Risk in Non-severe Hemophilia A. Frontiers in Immunology, 2020, 11, 1498.	4.8	0
31	Commentary on "Development of a novel fully functional coagulation factor VIII with reduced immunogenicity utilizing an in silico prediction and deimmunization approach――Will we ever be able to avoid inhibitor formation in hemophilia A?. Journal of Thrombosis and Haemostasis, 2021, 19, 2125-2126.	3.8	0
32	Managing Acquired Haemophilia (A): Pan London Experience-Relating to the European Acquired Haemophilia (EACH2) Registry Data. Blood, 2014, 124, 1512-1512.	1.4	0
33	New challenges for an expanding generation of older persons with haemophilia. The Journal of Haemophilia Practice, 2022, 9, 1-13.	0.4	0